Fri, February 10, 2017
Thu, February 9, 2017
Wed, February 8, 2017
Tue, February 7, 2017
Mon, February 6, 2017
Fri, February 3, 2017
Thu, February 2, 2017

Matthew Harrison Initiated (BMRN) at Buy and Held Target at $110 on, Feb 7th, 2017


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. -buy-and-held-target-at-110-on-feb-7th-2017.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Buy and Held Target at $110 on, Feb 7th, 2017.

Matthew has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Downgraded from Buy to Hold and Decreased Target to $105 on, Tuesday, November 29th, 2016
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold on, Monday, November 7th, 2016


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Kennen MacKay of "Credit Suisse" Initiated at Buy with Decreased Target to $107 on, Monday, January 23rd, 2017
  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016

Publication Contributing Sources